Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $9.80 Average Target Price from Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has earned a consensus rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $9.80.

A number of equities analysts have commented on AQST shares. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Leerink Partners upped their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Wednesday, November 6th.

Institutional Trading of Aquestive Therapeutics

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Aquestive Therapeutics by 71.7% during the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after acquiring an additional 1,353,518 shares in the last quarter. Blue Owl Capital Holdings LP increased its position in shares of Aquestive Therapeutics by 30.3% during the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after purchasing an additional 265,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at $594,000. Chartwell Investment Partners LLC acquired a new stake in shares of Aquestive Therapeutics in the 3rd quarter worth $535,000. Finally, Lazard Asset Management LLC grew its stake in Aquestive Therapeutics by 115.5% during the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after buying an additional 15,601 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Price Performance

Shares of NASDAQ AQST opened at $5.16 on Tuesday. Aquestive Therapeutics has a 1 year low of $1.84 and a 1 year high of $6.23. The firm has a 50-day simple moving average of $4.99 and a two-hundred day simple moving average of $3.97. The company has a market cap of $470.49 million, a P/E ratio of -11.47 and a beta of 2.82.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same period in the prior year, the company earned ($0.03) earnings per share. As a group, equities research analysts expect that Aquestive Therapeutics will post -0.47 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.